Fate Therapeutics
FATE
$4.04
Share price
6.45%
Change (1 day)
-33.36%
Change (1 year)
Categories
Fate Therapeutics (FATE) - P/B ratio
P/B ratio as of April 2024 : 1.17
According to Fate Therapeutics
's latest financial reports the company has a price-to-book ratio of 1.17.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Fate Therapeutics - P/B ratio (from 2013 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 1.00 | -50.59% |
| 2022-12-31 | 2.03 | -75.38% |
| 2021-12-31 | 8.23 | -60.11% |
| 2020-12-31 | 20.6 | 240.79% |
| 2019-12-31 | 6.06 | 17.07% |
| 2018-12-31 | 5.17 | 24.14% |
| 2017-12-31 | 4.17 | 193.43% |
| 2016-12-31 | 1.42 | -44.19% |
| 2015-12-31 | 2.54 | -30.31% |
| 2014-12-31 | 3.65 | 44.66% |
| 2013-12-31 | 2.52 | |
| 2012-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Becton Dickinson BDX | 2.64 | 125.00% | 🇺🇸 USA |
 Sarepta Therapeutics
SRPT | 14.2 | 1,106.67% | 🇺🇸 USA |
 PTC Therapeutics
PTCT | -2.67 | -327.83% | 🇺🇸 USA |
 Neurocrine Biosciences
NBIX | 6.13 | 422.16% | 🇺🇸 USA |
 Avidity Biosciences RNA | 3.88 | 230.44% | 🇺🇸 USA |